Ask AI

Two Drugs or Three? Navigating the Latest Evidence for Oral ART Initiation

Video
This activity is available for 1.75 CME/CE credit(s).

Released: October 23, 2026

Expiration: October 22, 2027

See Activity Collection

For decades, 3-drug regimens (3DRs) were considered the “gold standard” of antiretroviral therapy for HIV. However, numerous clinical trials and real-world studies demonstrated that modern 2-drug regimens (2DRs), both oral and long-acting injectable, are noninferior to 3DR alternatives. In this recording from a live webinar, expert faculty share practical frameworks and evidence to help you make confident, individualized decisions between 2DRs and 3DRs when initiating antiretroviral therapy.

Oral ART Initiation

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people living with HIV do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

In the phase IIIb VOGUE study of first line ART using a test-and-treat strategy, at Wk 48, compared with a BIC/FTC/TAF start, a DTG/3TC start had:

How confident are you in your answer?
4.

How would you counsel a person who is newly diagnosed with advanced HIV and wants to start a 2-drug ART? Initial ART with an oral 2-drug option is:

How confident are you in your answer?
5.

For an untreated person living with HIV, using an initial 2-drug oral ART regimen to achieve viral suppression before later switching to LA CAB + RPV is:

How confident are you in your answer?